LPS-induced knee-joint reactive arthritis and spinal cord glial activation were reduced after intrathecal thalidomide injection in rats

Life Sciences

Volumn 87, Issue 15-16, 2010, Pages 481-489

  Bressan, Elisângela ^a   Mitkovski, Mišo ^b,c   Tonussi, Carlos Rogério ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

Arthritis treatment; Dorsal root reflex; Neurogenic inflammation; Spinal cord; TNF

Indexed keywords

CARRAGEENAN; CD11B ANTIGEN; LIPOPOLYSACCHARIDE; THALIDOMIDE; ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL MIGRATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EDEMA; ESCHERICHIA COLI; IMMUNOREACTIVITY; LEUKOCYTE COUNT; LUMBAR SPINAL CORD; MALE; MICROGLIA; MONONUCLEAR CELL; MOTOR DYSFUNCTION; NERVE CELL INHIBITION; NONHUMAN; OUTCOME ASSESSMENT; POLYMORPHONUCLEAR CELL; RAT; REACTIVE ARTHRITIS; SYNOVIAL FLUID; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GLIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; KNEE; METABOLISM; PATHOPHYSIOLOGY; SPINAL CORD; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SPINAL; KNEE JOINT; LIPOPOLYSACCHARIDES; MALE; NEUROGLIA; RATS; RATS, WISTAR; SPINAL CORD; SYNOVIAL FLUID; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

ESCHERICHIA COLI; RATTUS;

EID: 77957755601     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.09.002     Document Type: Article

References (51)

1. Averbeck B., Reeh P.W., Michaelis M. Modulation of CGRP and PGE2 release from isolated rat skin by alpha-adrenoceptors and kappa-opioid-receptors. NeuroReport 2001, 12(10):2097-2100.
2. Baird R., van Zyl-Smit R.N., Iveson A., Duddy J., Rassam S.M. Thalidomide is highly effective in a patient with meningeal acute myeloid leukemia. Leukemia & Lymphoma 2004, 45(1):179-181.
3. Bao L., Zhu Y., Elhassan A.M., Wu Q., Xiao B., Zhu J., Lindgren J.U. Adjuvant-induced arthritis: IL-1 beta, IL-6 and TNF-alpha are up-regulated in the spinal cord. NeuroReport 2001, 12:3905-3908.
4. Bettoni I., Comelli F., Rossini C., Granucci F., Giagnoni G., Peri F., Costa B. Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia 2008, 56(12):1312-1219.
5. Boyle D.L., Jones T.L., Hammaker D., Svensson C.I., Rosengren S., Albani S., Sorkin L., Firestein G.S. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Medicine 2006, 3(9):1616-1624.
6. Bressan E., Tonussi C.R. Antiinflammatory effects of etoricoxib alone and combined with NSAIDs in LPS-induced reactive arthritis. Inflammation Research 2008, 57(12):586-592.
7. Bressan E., Cunha F.Q., Tonussi C.R. Contribution of TNFalpha, IL-1beta and CINC-1 for articular incapacitation, edema and cell migration in a model of LPS-induced reactive arthritis. Cytokine 2006, 36(1-2):83-89.
8. Chopra B., Giblett S., Little J.G., Donaldson L.F., Tate S., Evans R.J., Grubb B.D. Cyclooxygenase-1 is a marker for a subpopulation of putative nociceptive neurons in rat dorsal root ganglia. European Journal of Neuroscience 2000, 12(3):911-920.
9. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(9):4082-4055.
10. Fu K.Y., Light A.R., Matsushima G.K., Maixner W. Microglial reactions after subcutaneous formalin injection into the rat hind paw. Behavioural Brain Research 1999, 825(1-2):59-67.
11. García-Carrasco M., Fuentes-Alexandro S., Escárcega R.O., Rojas-Rodriguez J., Escobar L.E. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine: Revue du Rhumatisme 2007, 74(5):500-503.
12. Garrison C.J., Dougherty P.M., Kajander K.C., Carlton S.M. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Behavioural Brain Research 1991, 565(1):1-7.
13. Genovese T., Mazzon E., Esposito E., Di Paola R., Caminiti R., Meli R., Bramanti P., Cuzzocrea S. Effect of thalidomide on signal transduction pathways and secondary damage in experimental spinal cord trauma. Advances in Shock Research 2008, 30(3):231-240.
14. Goli V. Does thalidomide have an analgesic effect? Current status and future directions. Current Pain and Headache Reports 2007, 11(2):109-114.
15. Hains B.C., Waxman S.G. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. Canadian Journal of Neuroscience Nursing 2006, 26(16):4308-4317.
16. Holmes G.M., Hebert S.L., Rogers R.C., Hermann G.E. Immunocytochemical localization of TNF type 1 and type 2 receptors in the rat spinal cord. Behavioural Brain Research 2004, 1025:210-219.
17. Huang F., Gu J., Zhao W., Zhu J., Zhang J., Yu D.T. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis and Rheumatism 2002, 47(3):249-254.
18. IASP - International Association For Study of Pain Ethical guidelines for investigation of experimental pain in conscious animals. Pain 1983, 16:109-110.
19. Inada T., Kushida A., Sakamoto S., Taguchi H., Shingu K. Intrathecal betamethasone pain relief in cancer patients with vertebral metastasis: a pilot study. Acta Anaesthesiologica Scand 2007, 51(4):490-494.
20. Kwong Y.L., Yeung D.Y., Chan J.C. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Annals of Hematology 2009, 88(3):193-201.
21. Laffitte E., Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opinion on Drug Safety 2004, 3(1):47-56.
22. Lainer-Carr D., Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nature Clinical Practice Rheumatology 2007, 3(8):434-442.
23. Lehman T.J., Striegel K.H., Onel K.B. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. The American Journal of Pediatric Hematology/Oncology 2002, 140:125-127.
24. Lokensgard J.R., Hu S., Van Fenema E.M., Sheng W.S., Peterson P.K. Effect of thalidomide on chemokine production by human microglia. American Journal of Infectious Diseases 2000, 82(3):983-987.
25. Milligan E.D. Intrathecal HIV-1 envelope glycoprotein gp120 enhanced pain states mediated by spinal cord proinflammatory cytokines. Canadian Journal of Neuroscience Nursing 2001, 21:2808-2019.
26. Molander C., Xu Q., Grant G. The cytoarchitectonic organization of the spinal cord in the rat. I. The lower thoracic and lumbosacral cord. The Journal of Comparative Neurology 1984, 230:133-141.
27. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. Israel Journal of Experimental Medicine 1993, 177(6):1675-1680.
28. Nelson D.A. Dangers from methylprednisolone acetate therapy by intraspinal injection. Archives of Neurology 1988, 45(7):804-806.
29. O'Connor T.M., O'Connell J., O'Brien D.I., Goode T., Bredin C.P., Shanahan F. The role of substance P in inflammatory disease. Journal of Cellular Physiology 2004, 201(2):167-180.
30. Parada C.A., Yeh J.J., Joseph E.K., Levine J.D. Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat. European Journal of Neuroscience 2003, 17(9):1847-1852.
31. Peterson P.K., Hu S., Sheng W.S., Kravitz F.H., Molitor T.W., Chatterjee D., Chao C.C. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. The Journal of Infectious Disease 1995, 172(4):1137-1140.
32. Popovich P.G., Wei P., Stokes B.T. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. The Journal of Comparative Neurology 1997, 377:443-464.
33. Rasband WS: Image J. U. S. National Institutes of Health, Bethesda, Maryland, USA, 1997-2009 []. http://rsb.info.nih.gov/ij/.
34. Ribeiro R.A., Vale M.L., Ferreira S.H., Cunha F.Q. Analgesic effect of thalidomide on inflammatory pain. European Journal of Pharmacology 2000, 391(1-2):97-103.
35. Rocha A.C., Fernandes E.S., Quintão N.L.M., Campos M.M., Calixto J.B. Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. British Journal of Pharmacology 2006, 148:688-695.
36. Ryu J.K., McLarnon J.G. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiology of Disease 2008, 29(2):254-266.
37. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Israel Journal of Experimental Medicine 1991, 173(3):699-703.
38. Schäffer M., Beiter T., Becker H.D., Hunt T.K. Neuropeptides: mediators of inflammation and tissue repair?. Archives of Surgery 1998, 133(10):1107-1116.
39. Shenker N.G., Blake D.R., McCabe C.S., Haigh R., Mapp P.I. Symmetry, T cells and neurogenic arthritis. Novartis Foundation Symposium 2004, 260:241-252.
40. Sioka C., Kyritsis A.P. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemotherapy and Pharmacology 2009, 63(5):761-767.
41. Sluka K.A., Willis W.D., Westlund K.N. The role of dorsal root reflexes in neurogenic inflammation. Pain Forum 1995, 4:141-149.
42. Tonussi C.R., Ferreira S.H. Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain 1992, 48(3):421-427.
43. Tonussi C.R., Ferreira S.H. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 1999, 82(1):81-87.
44. Tweedie D., Sambamurti K., Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Current Alzheimer Research 2007, 4(4):378-385.
45. Umapathi T., Chaudhry V. Toxic neuropathy. Current Opinion in Neurology 2005, 18(5):574-580.
46. Vale M.L., Cunha F.Q., Brito G.A.C., Benevides V.M., Ferreira S.H., Poole S., Ribeiro R.A. Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation. European Journal of Pharmacology 2006, 536:309-317.
47. Watkins L.R., Milligan E.D., Maier S.F. Glial activation: a driving force for pathological pain. Trends in Neuroscience 2001, 24:450-455.
48. Wei J.C., Chan T.W., Lin H.S., Huang F., Chou C.T. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. British Journal of Rheumatology 2003, 30(12):2627-2631.
49. Willis W.D. Dorsal root potentials and dorsal root reflexes: a double-edged sword. Experimental Brain Research 1999, 124(4):395-421.
50. Wu C.L., Raja S.N. An update on the treatment of postherpetic neuralgia. The Journal of Pain 2008, 9:19-30.
51. Xu J.T., Xin W.J., Wei X.H., Wu C.Y., Ge Y.X., Liu Y.L., Zang Y., Zhang T., Li Y.Y., Liu X.G. p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Clinical and Experimental Neurology 2007, 204(1):355-365.